Trials / Completed
CompletedNCT00049790
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant human Angiostatin protein | |
| DRUG | paclitaxel | |
| DRUG | carboplatin |
Timeline
- Completion
- 2004-12-01
- First posted
- 2002-11-15
- Last updated
- 2009-01-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00049790. Inclusion in this directory is not an endorsement.